GSK hit with Cervarix application delay

After hearing that the FDA is demanding more information on Cervarix before it can be approved, analysts are estimating that GlaxoSmithKline could face delays of up to two years in launching the therapy in the U.S. That's a significant blow for the UK drug maker, which had been hoping to go head-to-head against Merck's Gardasil and replenish sales in the U.S.--which have been hit hard by dwindling sales of Avandia. Adding to the confusion and uncertainty, Glaxo declined to spell out exactly what the FDA is looking for. That could mean anything from a short delay of a few months to answer technical questions to a serious time lag as researchers harvest more data from ongoing clinical trials of the vaccine.

- see GSK's release on the setback
- here's the report on the delay from The Guardian

ALSO: Is Tykerb GSK's cancer breakthrough? Report

Related Articles:
GSK shakes up R&D. Report
It's Merck v. Glaxo in vaccine battle. Report
GSK prepares to go head-to-head with Merck. Report
Merck's Gardasil OK'd for pricey rollout. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.